Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366983722> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4366983722 endingPage "2298" @default.
- W4366983722 startingPage "2293" @default.
- W4366983722 abstract "Background/Aim: The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events, such as febrile neutropenia (FN), is high. This study retrospectively examined whether pegfilgrastim treatment reduces FN development during DCF therapy. Patients and Methods: This study evaluated 52 patients who were diagnosed with esophageal cancer and underwent DCF therapy at Jikei Daisan Hospital, Tokyo, Japan, between 2016 and 2020. They were divided into non-pegfilgrastim and pegfilgrastim-treated groups, and side-effects of chemotherapy and cost-effectiveness of pegfilgrastim were examined. Results: Eighty-six cycles of DCF therapy were conducted (33 and 53 cycles, respectively). FN was observed in 20 (60.6%) and seven (13.2%) cases, respectively (p<0.001). The lowest absolute neutrophil count during chemotherapy was significantly lower in the non-pegfilgrastim group (p<0.001), and the number of days until improvement from nadir was significantly shorter in the pegfilgrastim group (9 vs. 11 days; p<0.001). No significant difference was found in the onset of grade 2 or more adverse events by Common Terminology Criteria for Adverse Events. However, renal dysfunction was significantly lower in the pegfilgrastim group (30.7% vs. 60.6%, p=0.038). Hospitalization costs were also significantly lower in this group (692,839 vs. 879,431 Japanese yen, p=0.028). Conclusion: This study revealed the usefulness and cost-effectiveness of pegfilgrastim in prevention of FN in patients treated with DCF." @default.
- W4366983722 created "2023-04-27" @default.
- W4366983722 creator A5004462440 @default.
- W4366983722 creator A5007341857 @default.
- W4366983722 creator A5010052176 @default.
- W4366983722 creator A5038654104 @default.
- W4366983722 creator A5042417329 @default.
- W4366983722 creator A5042418170 @default.
- W4366983722 creator A5053717912 @default.
- W4366983722 creator A5086372970 @default.
- W4366983722 date "2023-04-25" @default.
- W4366983722 modified "2023-10-18" @default.
- W4366983722 title "Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer" @default.
- W4366983722 doi "https://doi.org/10.21873/anticanres.16393" @default.
- W4366983722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37097646" @default.
- W4366983722 hasPublicationYear "2023" @default.
- W4366983722 type Work @default.
- W4366983722 citedByCount "0" @default.
- W4366983722 crossrefType "journal-article" @default.
- W4366983722 hasAuthorship W4366983722A5004462440 @default.
- W4366983722 hasAuthorship W4366983722A5007341857 @default.
- W4366983722 hasAuthorship W4366983722A5010052176 @default.
- W4366983722 hasAuthorship W4366983722A5038654104 @default.
- W4366983722 hasAuthorship W4366983722A5042417329 @default.
- W4366983722 hasAuthorship W4366983722A5042418170 @default.
- W4366983722 hasAuthorship W4366983722A5053717912 @default.
- W4366983722 hasAuthorship W4366983722A5086372970 @default.
- W4366983722 hasConcept C126322002 @default.
- W4366983722 hasConcept C141071460 @default.
- W4366983722 hasConcept C143998085 @default.
- W4366983722 hasConcept C197934379 @default.
- W4366983722 hasConcept C2776694085 @default.
- W4366983722 hasConcept C2777063308 @default.
- W4366983722 hasConcept C2777793932 @default.
- W4366983722 hasConcept C2778658803 @default.
- W4366983722 hasConcept C2778850193 @default.
- W4366983722 hasConcept C2779134260 @default.
- W4366983722 hasConcept C2779171977 @default.
- W4366983722 hasConcept C2779920096 @default.
- W4366983722 hasConcept C2780456651 @default.
- W4366983722 hasConcept C2781190966 @default.
- W4366983722 hasConcept C43270747 @default.
- W4366983722 hasConcept C71924100 @default.
- W4366983722 hasConcept C90924648 @default.
- W4366983722 hasConceptScore W4366983722C126322002 @default.
- W4366983722 hasConceptScore W4366983722C141071460 @default.
- W4366983722 hasConceptScore W4366983722C143998085 @default.
- W4366983722 hasConceptScore W4366983722C197934379 @default.
- W4366983722 hasConceptScore W4366983722C2776694085 @default.
- W4366983722 hasConceptScore W4366983722C2777063308 @default.
- W4366983722 hasConceptScore W4366983722C2777793932 @default.
- W4366983722 hasConceptScore W4366983722C2778658803 @default.
- W4366983722 hasConceptScore W4366983722C2778850193 @default.
- W4366983722 hasConceptScore W4366983722C2779134260 @default.
- W4366983722 hasConceptScore W4366983722C2779171977 @default.
- W4366983722 hasConceptScore W4366983722C2779920096 @default.
- W4366983722 hasConceptScore W4366983722C2780456651 @default.
- W4366983722 hasConceptScore W4366983722C2781190966 @default.
- W4366983722 hasConceptScore W4366983722C43270747 @default.
- W4366983722 hasConceptScore W4366983722C71924100 @default.
- W4366983722 hasConceptScore W4366983722C90924648 @default.
- W4366983722 hasIssue "5" @default.
- W4366983722 hasLocation W43669837221 @default.
- W4366983722 hasLocation W43669837222 @default.
- W4366983722 hasOpenAccess W4366983722 @default.
- W4366983722 hasPrimaryLocation W43669837221 @default.
- W4366983722 hasRelatedWork W1995429954 @default.
- W4366983722 hasRelatedWork W2037732945 @default.
- W4366983722 hasRelatedWork W2053128632 @default.
- W4366983722 hasRelatedWork W2121985645 @default.
- W4366983722 hasRelatedWork W2320262955 @default.
- W4366983722 hasRelatedWork W2955643363 @default.
- W4366983722 hasRelatedWork W2961715232 @default.
- W4366983722 hasRelatedWork W2982282342 @default.
- W4366983722 hasRelatedWork W3088375154 @default.
- W4366983722 hasRelatedWork W4366983722 @default.
- W4366983722 hasVolume "43" @default.
- W4366983722 isParatext "false" @default.
- W4366983722 isRetracted "false" @default.
- W4366983722 workType "article" @default.